Last reviewed · How we verify
dry misoprostol
dry misoprostol is a Small molecule drug developed by Hospital de Clinicas de Porto Alegre. It is currently FDA-approved.
Dry misoprostol, marketed by Hospital de Clinicas de Porto Alegre, holds a niche position in the pharmaceutical market. The key composition patent expiring in 2028 provides a period of exclusivity that may help maintain market share. The primary risk is the lack of clear primary indication and revenue data, which could impact strategic planning and market competitiveness.
At a glance
| Generic name | dry misoprostol |
|---|---|
| Sponsor | Hospital de Clinicas de Porto Alegre |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Saving Lives at Birth in Uganda: Building and Sustaining Capacity of Frontline Health Workers - A Program Evaluation (NA)
- Dry vs Wet Misoprostol for Cervical Dilation in First Trimester Abortion (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dry misoprostol CI brief — competitive landscape report
- dry misoprostol updates RSS · CI watch RSS
- Hospital de Clinicas de Porto Alegre portfolio CI
Frequently asked questions about dry misoprostol
What is dry misoprostol?
Who makes dry misoprostol?
What development phase is dry misoprostol in?
Related
- Manufacturer: Hospital de Clinicas de Porto Alegre — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing